Clinical Trial Update: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Niraparib (Niraparib)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Castration-Resistant Prostatic Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-10-04